A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV

PURPOSE OF REVIEW: Cabotegravir (CAB) and rilpivirine (RPV) is the first long-acting injectable antiretroviral therapy (ART) option approved for virologically suppressed adults with HIV-1. In addition, long-acting CAB is a promising agent for HIV preexposure prophylaxis (PrEP). This review focuses o...

Descripción completa

Detalles Bibliográficos
Autores principales: Bares, Sara H., Scarsi, Kimberly K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
NEW DRUGS: Edited by Charles W. Flexner and Angela Kashuba
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694245/
https://www.ncbi.nlm.nih.gov/pubmed/34871188
http://dx.doi.org/10.1097/COH.0000000000000708

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694245/
https://www.ncbi.nlm.nih.gov/pubmed/34871188
http://dx.doi.org/10.1097/COH.0000000000000708

Ejemplares similares